Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long term treatment with rio...
保存先:
主要な著者: | , , , , , , , , , , , , , , , |
---|---|
フォーマット: | Artigo |
言語: | 英語 |
出版事項: |
2018
|
オンライン・アクセス: | https://doi.org/10.1186/s12931-018-0957-y https://respiratory-research.biomedcentral.com/track/pdf/10.1186/s12931-018-0957-y |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|